Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MILLENDO THERAPEUTICS logo — Relentlessly pursuing therapies that alleviate patient suffe...

MILLENDO THERAPEUTICS

Relentlessly pursuing therapies that alleviate patient suffering due to orphan endocrine disease

Founded 2011 United States Ann Arbor, United States 3 employees Post Ipo Equity Total: $191.52M Biotechnology, Health and Wellness +1

General Information

Company Name MILLENDO THERAPEUTICS
Founded Year 2011
Location United States Ann Arbor, United States +2
Employees 3
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Post Ipo Equity
Social

Get notified when MILLENDO THERAPEUTICS moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MILLENDO THERAPEUTICS

MILLENDO THERAPEUTICS is a biotechnology startup founded in 2011. The company is dedicated to relentlessly pursuing therapies that alleviate patient suffering due to orphan endocrine disease. Millendo Therapeutics aims to address unmet medical needs by developing novel treatments for endocrine diseases. The company's focus is on creating distinct and transformative treatments for a wide range of diseases. Currently, Millendo Therapeutics is advancing two promising product candidates: livoletide (AZP-531) for Prader-Willi syndrome and nevanimibe (ATR-101) for the treatment of Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS). The company's headquarters is based in the United States. In March 2020, Millendo Therapeutics secured a $50.00MPost-IPO Equity investment. Despite not stating the specific investors involved, this substantial investment indicates increasing confidence in the company's potential and its ability to make a significant impact in the biotechnology industry.

Taxonomy: Millendo Therapeutics, endocrine diseases, novel treatments, Livoletide, Nevanimibe, Prader-Willi syndrome, orphan adrenal diseases, Congenital Adrenal Hyperplasia, Cushing’s Syndrome, biotech, pharmaceuticals, Endocrinology

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 01 Mar 2020
Post-IPO Equity •••••• - 04 Dec 2019
Venture Round •••••• 8
Investor Investor Investor Investor Investor
•••• •••• 		09 Aug 2018
Series B •••••• 9
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		05 Jan 2016
Private Equity Round •••••• - 26 Feb 2013

View All 6 Funding Rounds

MILLENDO THERAPEUTICS Alternatives & Competitors

MILLENDO THERAPEUTICS vs
Neurocrine Biosciences
Neurocrine Biosciences United States

You Deserve Brave Science

IPO
2403 employees
Biotechnology
MILLENDO THERAPEUTICS vs
Spruce Biosciences
Spruce Biosciences United States

Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders

Post Ipo Equity
27 employees
Biopharma, Biotechnology
Compare MILLENDO THERAPEUTICS vs Spruce Biosciences
MILLENDO THERAPEUTICS vs
APTIMMUNE BIOLOGICS, INC.
APTIMMUNE BIOLOGICS, INC. United States

Aptimmune specializes in developing revolutionary mucosal vaccines, made with Barricade(TM) Formulat...

Seed
6 employees

FAQ About MILLENDO THERAPEUTICS

Relentlessly pursuing therapies that alleviate patient suffering due to orphan endocrine disease
MILLENDO THERAPEUTICS was founded in 2011.
MILLENDO THERAPEUTICS is headquartered in Ann Arbor, United States.
MILLENDO THERAPEUTICS operates in the following industries: Biotechnology, Health and Wellness, Life Sciences.
MILLENDO THERAPEUTICS has approximately 3 employees.
MILLENDO THERAPEUTICS has completed 6 funding rounds, raising a total of $191.52M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to MILLENDO THERAPEUTICS include Neurocrine Biosciences, Spruce Biosciences, APTIMMUNE BIOLOGICS, INC., CSI Pharmacy, Mirum Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MILLENDO THERAPEUTICS and Neurocrine Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MILLENDO THERAPEUTICS and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy